Bumetanide Versus Furosemide in Heart Failure

Lawson Health Research Institute

Status and phase

Withdrawn

Phase 3

Conditions

Heart Failure

Treatments

Drug: Bumetanide

Drug: furosemide

Drug: Furosemide

Drug: bumetanide

Study type

Interventional

Funder types

Other

Identifiers

NCT00372762

R-06-415

Details and patient eligibility

About

Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed.

Full description

Insulin resistance is common in patients with heart failure (HF) and is associated with a worse functional capacity and more severe symptoms of heart failure. The majority of HF patients take furosemide on at least a daily basis for symptom relief. Bumetanide is a loop diuretic with a similar therapeutic diuretic effect to furosemide. There is evidence from observational and small comparative trials that bumetanide has a significantly less deleterious effect on indirect measures of insulin resistance compared with furosemide. However, a formal comparison between the 2 drugs using rigorous measures of insulin resistance has never been conducted in patients with HF. If bumetanide can be demonstrated to have a similar diuretic and a superior (less deleterious) effect on insulin resistance in patients with HF, the potential exists for bumetanide to have a significantly reduced morbidity in patients with heart failure compared to furosemide. In order to prepare for such a study, the variance of the MINMOD-derived insulin resistance from the FSIGT (26), in this group of patient needs to be determined along with the feasibility of conducting such a study. Functional capacity will be determined by duplicate 6-minute walk tests.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and women ≥18 years of age
NHYA FC II or III HF AND documented LVEF ≤40% within 6 months prior to study entry
Taking 20 mg to 80 mg furosemide orally once or twice per day
No changes to cardiac medications for 3 months prior to study entry and no anticipated changes of medications for the duration of the study
No changes to oral anti-diabetic medications (if applicable) for 3 months prior to study entry, and no anticipated changes for the duration of the study (metformin, sulphonylurea type, glitazone type)
Ability to provide written consent

Exclusion criteria

Known sensitivity to bumetanide
Myocardial infarction, coronary angioplasty, coronary artery bypass surgery, admission for HF or unstable angina within a 3 month period prior to study recruitment
Planned coronary intervention within 6 months
Patients who are taking insulin
Patients with chronic renal (serum creatinine ≥ 200 μmol/L) or hepatic impairment (known cirrhosis or AST or ALT > 1.5 x upper limit of normal)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups

Furosemide

Active Comparator group

Description:

Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.

Treatment:

Drug: Furosemide

Bumetanide

Active Comparator group

Description:

Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.

Treatment:

Drug: Bumetanide

Trial contacts and locations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms